



VGX Pharmaceuticals Announces Formation of Animal Health Company

Blue Bell, PA – May 31, 2007 –

VGX Pharmaceuticals Inc. (“VGX”) announced today that it has formed a wholly owned subsidiary, VGX Animal Health, Inc. (“VGX AH”). The newly established company will include the animal health intellectual property and technology that came to VGX as a result of its acquisition of ADViSYS in February of this year. Additionally, VGX AH will have access to VGX’s adaptive electroporation device, Collectra™ for all animal health applications.

The VGX AH pipeline includes proprietary Growth Hormone Releasing Hormone (“GHRH”) plasmid technology for major food and companion animals. The company’s lead product, Life Tide SW5™ a GHRH porcine product, is currently in registration in Australia. Also in Phase II of development are canine GHRH products for renal failure and cancer related cachexia and anemia. VGX AH has multiple product candidates in Phase I, including indications for equine laminitis and arthritis.

VGX AH will be seeking alliance partners to help in its development and commercialization efforts in major markets throughout the world.

Dr. J. Joseph Kim, President and CEO of VGX Pharmaceuticals, commented, “The formation of VGX AH will allow us to maximize the commercial potential of this important portfolio of animal health technologies, while at the same time allowing us to maintain focus on the continued development and expansion of our core human health biopharmaceutical business opportunities.”

Cautionary Factors That May Affect Future Results - Materials in this Press Release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on www.vgxp.com as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

About VGX Pharmaceuticals

VGX Pharmaceuticals is a biopharmaceutical company with small molecule and biologic product candidates for the treatment of infectious diseases, cancer, and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection, which is in Phase II clinical trials, and PENNVAX™-B, a DNA vaccine for preventing HIV infection, which is in Phase I clinical trials. In addition, VGX is planning to initiate Phase I clinical studies for VGX-1027, its lead compound for inflammatory diseases. VGX's research pipeline includes a new generation of SynCon™ DNA vaccines and therapeutics as well as the CELLECTRA™ electroporator, a patented DNA delivery device. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

Company Contact:

Kevin W. Rassas

Senior Vice President

Tel. 267.440.4208

Fax 267.440.4242

E-mail: Rassas@vgxp.com

www.vgxp.com